Related Experiment Video
Updated: Jun 4, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years
Fred Fyles1, Rachel Burton1, Amy Nuttall1
1Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Abstract:
Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
COPD: Management Using Bronchodilators and Corticosteroids
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

